SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Federici A B)
 

Sökning: WFRF:(Federici A B) > (2010-2014) > Prophylaxis in seve...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00003796naa a2200541 4500
001oai:lup.lub.lu.se:e05b32d0-f8ba-481d-aabc-3f2c9b96967a
003SwePub
008160401s2013 | |||||||||||000 ||eng|
0247 a https://lup.lub.lu.se/record/35897832 URI
0247 a https://doi.org/10.1111/j.1365-2516.2012.02916.x2 DOI
040 a (SwePub)lu
041 a engb eng
042 9 SwePub
072 7a art2 swepub-publicationtype
072 7a ref2 swepub-contenttype
1001 a Abshire, T. C.4 aut
2451 0a Prophylaxis in severe forms of von Willebrand's disease: results from the von Willebrand Disease Prophylaxis Network (VWD PN)
264 c 2012-07-23
264 1b Wiley,c 2013
520 a The bleeding patterns of severe von Willebrand's disease (VWD) adversely affect quality of life, and may be life threatening. There is a presumed role for prophylaxis with VWF-containing concentrates, but data are scarce. The von Willebrand Disease Prophylaxis Network (VWD PN) was formed to investigate the role of prophylaxis in clinically severe VWD that is not responsive to other treatment(s). Using a retrospective design, the effect of prophylaxis was studied. Availability of records to document, or reliably assess, the type and frequency of bleeding episodes prior to, and after, the initiation of prophylaxis was required. Annualized bleeding rates were calculated for the period prior to prophylaxis, during prophylaxis and by primary bleeding indication defined as the site accounting for more than half of all bleeding symptoms. The Wilcoxon signed-rank test of differences in the medians was used. Sixty-one subjects from 20 centres in 10 countries were enrolled. Data for 59 were used in the analysis. The median age at onset of prophylaxis was 22.4 years. Type 3 VWD accounted for the largest number (N = 34, 57.6%). Differences in bleeding rates within individuals during compared with before prophylaxis were significant for the total group (P < 0.0001), and for those with primary bleeding indications of epistaxis (P = 0.0005), joint bleeding (P = 0.002) and GI bleeding (P = 0.001). The effect of prophylaxis was similar among those age < 18 years and those >= 18. One person developed an inhibitor during treatment. We conclude that prophylactic treatment of VWD is efficacious.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Hematologi0 (SwePub)302022 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Hematology0 (SwePub)302022 hsv//eng
653 a bleeding rate
653 a epistaxis
653 a gastrointestinal bleeding
653 a joint bleeding
653 a prophylaxis
653 a severe VWD
7001 a Federici, A. B.4 aut
7001 a Alvarez, M. T.4 aut
7001 a Bowen, J.4 aut
7001 a Carcao, M. D.4 aut
7001 a Gill, J. Cox4 aut
7001 a Key, N. S.4 aut
7001 a Kouides, P. A.4 aut
7001 a Kurnik, K.4 aut
7001 a Lail, A. E.4 aut
7001 a Leebeek, F. W. G.4 aut
7001 a Makris, M.4 aut
7001 a Mannucci, P. M.4 aut
7001 a Winikoff, R.4 aut
7001 a Berntorp, Eriku Lund University,Lunds universitet,Klinisk koagulationsmedicin, Malmö,Forskargrupper vid Lunds universitet,Clinical Coagulation, Malmö,Lund University Research Groups4 aut0 (Swepub:lu)medf-ebe
7102 a Klinisk koagulationsmedicin, Malmöb Forskargrupper vid Lunds universitet4 org
7730 t Haemophiliad : Wileyg 19:1, s. 76-81q 19:1<76-81x 1351-8216
8564 u http://dx.doi.org/10.1111/j.1365-2516.2012.02916.xy FULLTEXT
8564 u https://europepmc.org/articles/pmc4514514?pdf=render
8564 8u https://lup.lub.lu.se/record/3589783
8564 8u https://doi.org/10.1111/j.1365-2516.2012.02916.x

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy